摘要
目的观测原发性肝癌患者经肝动脉化疗栓塞(TAE)+^(32)P内照射治疗以及单纯TAE治疗后患者可溶性白细胞介素2受体(sIL—2R)、T淋巴细胞亚群免疫功能状态的改变并进行比较。方法采用双抗体夹心法和APAAP法测定患者血清sIL—2R、T淋巴细胞亚群。结果我们检测23例TAE+^(32)P、31例单纯TAE治疗原发性肝癌患者和20例健康献血员sIL—2R、辅肋T淋巴细胞、抑制T淋巴细胞。发现原发性肝癌患者Th细胞比健康对照组显著下降,(p<0.05),TAE+^(32)P治疗后恢复至正常水平。原发性肝癌患者sIL—2R、Ts细胞比健康对照组明显增高,(p<0.05);TAE+^(32)P、TAE治疗后原发性肝癌患者sIL—2R、Ts细胞非常显著降低(p<0.05),TAE+^(32)P比TAE下降更显著,(p<0.05)。结论 TAE+^(32)P治疗原发性肝癌比单纯TAE治疗患者血液中sIL—2R下降更显著,两种治疗方法可使患者Th增高、Ts下降。测定原发性肝癌患者血液中sIL—2R、T淋巴细胞亚群对判断患者免疫功能状态、疗效、预后有一定的价值。
In order to obtain immune state in patients with liver cancer after transcatheter hepatic artery embolization(TAE)+^(32)P and TAE serum soluble interleukin 2 receptor and T lymphocytes subsets were derarmnedin 23 patients with liver cancer treated with TAE+^(32) P、31 patients with liver cancer treated with TAE and 20 health members. Result: The results showed that Help T cells Th in patients with liver cancer are lower than that in control group, (p<0.05), but recover to normal lever after TAE+^(32)P or TAE. sIL-2R, Suppress T cells in Ts patients with liver cancer are higher significantly than that in control group, (p<0.05). sIL-2R, Ts cells become lower remarkably than that of in normal group after TAE+^(32)P (p<0.01) or TAE, (p<0.01), (p<0.05), serum sIL-2R in patients with liver cancer after TAE+^(32)P further decrease than that after TAE, (p<0.05). Conclusion: Serum sIL-2R in patients with liver cancer after TAE+^(32)P is lower significantly than that after TAE. The two therapy methods can decrease serum soluble interleukin 2 receptor and T lymphocytes subsets. It have a certain value for us to identify immune, state, treating effect and prognosis in patients with liver cancer in whom we measured Th, Ts cells and sIL-2R after TAE+^(32)P and TAE.
